Ser403
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser403  -  PML (human)

Site Information
AAVskkAsPEAAstP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3189643
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 ) , mass spectrometry (in vitro) ( 39 ) , mutation of modification site ( 39 )
Disease tissue studied:
breast cancer ( 8 , 9 , 19 ) , breast ductal carcinoma ( 8 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 8 ) , cervical cancer ( 65 ) , cervical adenocarcinoma ( 65 ) , leukemia ( 23 , 25 ) , acute myelogenous leukemia ( 23 ) , T cell leukemia ( 25 ) , liver cancer ( 43 , 44 , 50 , 52 , 54 ) , hepatocellular carcinoma, surrounding tissue ( 61 ) , liver cancer, surrounding tissue ( 45 , 48 , 51 , 53 ) , lung cancer ( 6 , 12 , 13 , 14 , 19 , 39 , 72 ) , non-small cell lung cancer ( 12 , 13 , 17 , 19 , 72 ) , non-small cell lung adenocarcinoma ( 6 , 12 , 13 , 14 , 17 ) , non-small cell large cell lung carcinoma ( 12 ) , ovarian cancer ( 8 ) , pancreatic ductal adenocarcinoma ( 11 ) , melanoma skin cancer ( 5 ) , teratoma, surrounding tissue ( 47 ) , thyroid cancer ( 46 ) , thyroid cancer, surrounding tissue ( 49 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 24 ) , 'pancreatic, ductal'-pancreas ( 11 ) , 293 (epithelial) ( 40 ) , A498 (renal) ( 55 ) , A549 (pulmonary) ( 39 ) , breast ( 2 , 8 ) , BT-20 (breast cell) ( 19 ) , BT-549 (breast cell) ( 19 ) , Cal-12T (pulmonary) ( 13 ) , Calu 6 (pulmonary) ( 19 ) , endothelial-aorta ( 20 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 21 ) , Flp-In T-Rex-293 (epithelial) ( 21 ) , germ cell-teratoma ( 47 ) , GM00130 (B lymphocyte) ( 42 ) , H2009 (pulmonary) ( 19 ) , H2077 (pulmonary) ( 19 ) , H2887 (pulmonary) ( 19 ) , H322M (pulmonary) ( 19 ) , HCC1359 (pulmonary) ( 19 ) , HCC1937 (breast cell) ( 19 ) , HCC2279 (pulmonary) ( 19 ) , HCC366 (pulmonary) ( 19 ) , HCC4006 (pulmonary) ( 19 ) , HCC44 (pulmonary) ( 13 ) , HCC78 (pulmonary) ( 12 , 19 ) , HEK293T (epithelial) ( 4 ) , HeLa (cervical) ( 1 , 7 , 26 , 31 , 33 , 34 , 36 , 37 , 38 , 39 , 66 , 73 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 32 ) , HeLa S3 (cervical) ( 32 , 65 ) , hepatocyte-liver ( 61 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 9 ) , HMLER ('stem, breast cancer') ( 9 ) , HOP62 (pulmonary) ( 19 ) , Jurkat (T lymphocyte) ( 15 , 27 , 28 , 29 , 30 , 35 , 41 , 56 , 57 , 58 , 59 , 60 , 62 , 63 , 64 , 67 , 68 , 69 , 70 , 71 , 74 ) , K562 (erythroid) ( 18 , 66 ) , KG-1 (myeloid) ( 23 ) , Kit225 (T lymphocyte) ( 25 ) , liver ( 10 , 43 , 44 , 45 , 48 , 50 , 51 , 52 , 53 , 54 ) , LOU-NH91 (squamous) ( 19 ) , lung ( 12 , 13 , 14 ) , MCF-7 (breast cell) ( 19 ) , MDA-MB-231 (breast cell) ( 19 ) , MDA-MB-468 (breast cell) ( 19 ) , MEF (fibroblast) ( 39 ) , NCI-H1299 (pulmonary) ( 72 ) , NCI-H1395 (pulmonary) ( 19 ) , NCI-H1437 (pulmonary) ( 13 ) , NCI-H1568 (pulmonary) ( 19 ) , NCI-H157 (pulmonary) ( 19 ) , NCI-H1648 (pulmonary) ( 19 ) , NCI-H1666 (pulmonary) ( 13 , 19 ) , NCI-H1781 (pulmonary) ( 12 ) , NCI-H2030 (pulmonary) ( 19 ) , NCI-H2172 (pulmonary) ( 19 ) , NCI-H2228 (pulmonary) ( 12 , 17 ) , NCI-H2405 (pulmonary) ( 13 ) , NCI-H3122 (pulmonary) ( 12 ) , NCI-H322 (pulmonary) ( 19 ) , NCI-H460 (pulmonary) ( 19 ) , NCI-H520 (squamous) ( 19 ) , NCI-H647 (pulmonary) ( 19 ) , NCI-H661 (pulmonary) ( 12 ) , ovary ( 8 ) , PC9 (pulmonary) ( 6 , 19 ) , thyroid ( 46 , 49 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Kinases, in vitro:
ERK5 (human) ( 39 )
Treatments:
nocodazole ( 65 )

Downstream Regulation
Effects of modification on biological processes:
carcinogenesis, altered ( 39 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

5

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

6

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

7

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

8

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

9

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

10

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

11

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

15

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

16

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

17

Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

18

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

19

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

20

Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81
22497526   Curated Info

21

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

22

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

23

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

24

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

25

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

26

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

27

Guo A (2011) CST Curation Set: 12058; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

28

Guo A (2011) CST Curation Set: 12061; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

29

Guo A (2011) CST Curation Set: 12062; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

30

Guo A (2011) CST Curation Set: 12064; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

31

Guo A (2011) CST Curation Set: 11453; Year: 2011; Biosample/Treatment: cell line, HeLa/nocodazole &'||' pervanadate; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

32

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

33

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

34

Zhou J (2010) CST Curation Set: 10712; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

35

Possemato A (2010) CST Curation Set: 10722; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

36

Zhou J (2010) CST Curation Set: 10713; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

37

Zhou J (2010) CST Curation Set: 10691; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

38

Zhou J (2010) CST Curation Set: 10690; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

39

Yang Q, et al. (2010) Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18, 258-67
20832753   Curated Info

40

Guo A (2010) CST Curation Set: 9970; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

41

Possemato A (2010) CST Curation Set: 10051; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

42

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

43

Tucker M (2010) CST Curation Set: 9850; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

44

Tucker M (2010) CST Curation Set: 9824; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

45

Tucker M (2010) CST Curation Set: 9831; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

46

Tucker M (2010) CST Curation Set: 9848; Year: 2010; Biosample/Treatment: tissue, thyroid/untreated; Disease: thyroid cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

47

Tucker M (2010) CST Curation Set: 9847; Year: 2010; Biosample/Treatment: cell line, xy3-145N/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

48

Tucker M (2010) CST Curation Set: 9851; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

49

Tucker M (2010) CST Curation Set: 9849; Year: 2010; Biosample/Treatment: tissue, thyroid/untreated; Disease: thyroid cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

50

Tucker M (2010) CST Curation Set: 9854; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

51

Tucker M (2010) CST Curation Set: 9839; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

52

Tucker M (2010) CST Curation Set: 9840; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

53

Tucker M (2010) CST Curation Set: 9837; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

54

Tucker M (2010) CST Curation Set: 9844; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

55

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

56

Possemato A (2010) CST Curation Set: 9437; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

57

Possemato A (2010) CST Curation Set: 9438; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

58

Possemato A (2010) CST Curation Set: 9290; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

59

Possemato A (2010) CST Curation Set: 9291; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

60

Possemato A (2010) CST Curation Set: 9292; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

61

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

62

Possemato A (2010) CST Curation Set: 8973; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

63

Possemato A (2010) CST Curation Set: 8987; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

64

Possemato A (2010) CST Curation Set: 8995; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

65

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

66

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

67

Possemato A (2009) CST Curation Set: 6354; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

68

Possemato A (2008) CST Curation Set: 5273; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

69

Possemato A (2008) CST Curation Set: 5274; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

70

Possemato A (2008) CST Curation Set: 5275; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

71

Possemato A (2008) CST Curation Set: 5276; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

72

Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69
18707149   Curated Info

73

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

74

Zhou J (2008) CST Curation Set: 4705; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info